Tired of trying to read science papers?
​Here's a straightforward summary of the 2026 Utrecht University DCM Study. 

Want to read the detailed, published research paper?
Click HERE.

Overview of the Study

Dilated cardiomyopathy (DCM) is a severe, life-threatening heart disease that causes the heart muscle to become weak and enlarged. It is the second most common heart disease in dogs, but it hits Doberman Pinschers especially hard. Research shows that up to 58% of Dobermans eventually develop DCM, with the risk climbing sharply as they get older. Affected dogs can suffer from sudden heart failure or collapse without warning.

Because DCM is so widespread in Dobermans, scientists know genetics play a major role. However, Dobermans split into two distinct genetic groups over a century ago: North American lines and European lines. For years, commercial DNA tests have looked for different gene mutations depending on the region:

• DCM1 (PDK4) and DCM2 (TTN): Discovered in North American dogs.
• DCM3 (PRKAA2) and DCM4 (RNF207): Discovered in European dogs on chromosome 5.

This study evaluated over 5,000 Dobermans to determine whether these genetic markers are genuinely linked to heart disease across both populations.

Key Findings

• DCM4 (RNF207) is a real, shared risk factor: The mutation in the RNF207 gene was strongly linked to heart disease in both European and North American Dobermans. It acts mostly as a recessive trait, meaning a dog that inherits two copies of this mutation (one from each parent) has about five times higher odds of developing DCM compared to a dog with zero copies. Carrying just one copy gives only a slight increase in risk.
• DCM1 (PDK4) and DCM2 (TTN) showed no clear link: Despite being widely used in commercial tests for North American Dobermans, markers near these two genes showed no meaningful association with DCM in this study. This matches recent findings from European and UK research, raising serious questions about whether these two mutations actually cause the disease.
• DCM3 (PRKAA2) showed a weaker, inconsistent link: In the European group, each copy of the DCM3 risk variant progressively increased the odds of heart disease. However, that connection faded when looking specifically at the North American group, where the mutation was much less common.
• Males face higher overall risk: Across all genetic combinations, male Dobermans developed DCM more frequently than females.

What This Means for Breeders and Owners

• DNA tests do not tell the whole story: While DCM4 (RNF207) is a legitimate risk factor, it has low predictive sensitivity. Many dogs with DCM do not have the mutation, and some dogs carrying the mutation live long, healthy lives. DCM is a complex disease involving multiple genes and environmental factors.
• Do not eliminate carriers from breeding: Because the RNF207 risk variant is so widespread—found in more than half of the North American population—immediately banning carrier dogs from breeding programs would severely shrink the breed's gene pool. Loss of genetic diversity can accidentally introduce other dangerous health problems.
• Use DNA tests to guide medical monitoring, not replace it: DNA testing cannot replace regular hands-on cardiac exams. Dogs carrying two copies of the RNF207 variant should simply be prioritized for earlier and more frequent veterinary heart checks (such as ultrasounds and 24-hour Holter monitor vests).
• Stop relying heavily on DCM1 and DCM2: Breeding decisions based on markers that fail to replicate in large-scale studies risk removing healthy dogs from the breeding pool for no genuine medical benefit.

How the Study Was Conducted

The researchers combined data from three large sources:

1. Discovery Cohort (440 European dogs): Dogs thoroughly evaluated using veterinary heart exams.
2. Replication Cohort (1,766 primarily North American dogs): Dogs tested through Embark, whose owners completed detailed health questionnaires.
3. Diversity Cohort (2,872 dogs): Genetic data provided through the Doberman Diversity Project to measure how common these mutations are across the broader breed population.

Using advanced computer modeling, the team standardized the genetic data across different testing platforms to compare 462,386 genetic markers side by side.

Study Limitations

• Owner-Reported Health Records: The North American replication group relied heavily on owner surveys rather than standardized veterinary records. While researchers excluded young dogs to ensure "control" dogs were truly healthy, early-stage DCM can go unnoticed without regular clinical heart scans.
• Direct Marker Testing: The study examined the specific chromosomal regions surrounding PDK4 and TTN rather than sequencing those exact mutations directly, though the surrounding genetic markers provided strong coverage of those areas.